Intellia deal expands Regeneron’s reach into CRISPR therapies

Fresh off Sanofi’s sell-off, Regeneron announced an expanded collaboration with gene editing company Intellia that gives the big biotech access to the coveted CRISPR gene editing technology for additional targets and indications, including hemophilia.

The new deal, which is an extension of a 2016 collaboration, gives Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) rights to five new liver targets for in vivo therapies based on the CRISPR-Cas9 technology, bringing the total to 15. Regeneron also gains a non-exclusive license to Intellia IP to develop and commercialize up to 10 ex vivo CRISPR-Cas9 products in undisclosed cell types. ...